The ability of Mouse TNF-α Neutralizing (D2H4) Rabbit mAb to inhibit mTNF-α-induced L-929 cell cytotoxicity was assessed. Cells were incubated with increasing concentrations of antibody in the presence of mTNF-α #5178 (250 pg/ml) and 1 µg/ml actinomycin D. After 24 hr, viable cells were detected by incubation with a tetrazolium salt and the OD450 was determined.Learn more about how we get our images
The viability of L-929 cells treated with increasing amounts of mTNF-α #5178 in the presence of 1 µg/ml actinomycin D was determined. After a 24 hr treatment, cells were incubated with a tetrazolium salt and the OD450 was determined.Learn more about how we get our images
CST recommends incubation of the neutralizing antibody with the intended target for 1 hr at 37ºC before addition to the experiment at an optimal concentration determined by the user.
Lyophilized from a 0.2 µm filtered solution in 10mM HEPES with trehalose.
Store lyophilized material at -20ºC. After reconstitution, recommended storage at 4ºC for 1 month or -20ºC for 6 months. Avoid repeated freeze/thawing.
Mouse TNF-α Neutralizing (D2H4) Rabbit mAb binds to mouse TNF-α and neutralizes its cytotoxic effects. This antibody does not cross-react with human TNF-α or human LTA.
Monoclonal antibody is produced by immunizing animals with a recombinant mouse TNF-α protein.
Neutralizing antibodies can be used to inhibit normal biological function through their binding to biological molecules. These reagents can be used to determine the effects that a particular molecule has in biological systems. Mouse TNF-α Neutralizing (D2H4) Rabbit mAb has been shown to neutralize the cytotoxic effects of TNF-α in L-929 cells in vitro with an ND50 in the range of 1-6 ng/ml.
<0.1 EU/µg of antibody
TNF-α, the prototypical member of the TNF protein superfamily, is a homotrimeric type-II membrane protein (1,2). Membrane-bound TNF-α is cleaved by the metalloprotease TACE/ADAM17 to generate a soluble homotrimer (2). Both membrane and soluble forms of TNF-α are biologically active. TNF-α is produced by a variety of immune cells including T cells, B cells, NK cells, and macrophages (1). Cellular response to TNF-α is mediated through interaction with receptors TNF-R1 and TNF-R2, and results in activation of pathways that favor both cell survival and apoptosis depending on the cell type and biological context. Activation of kinase pathways (including JNK, Erk (p44/42), p38 MAPK, and NF-κB) promotes the survival of cells, while TNF-α-mediated activation of caspase-8 leads to programmed cell death (1,2). TNF-α plays a key regulatory role in inflammation and host defense against bacterial infection, notably Mycobacterium tuberculosis (3). The role of TNF-α in autoimmunity is underscored by research studies that show that blocking TNF-α action may be used to treat rheumatoid arthritis and Crohn’s disease (1,2,4).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.